Abstract: Provided is a method of preventing, treating or delaying progression of a disease involving aberrant fibroblast proliferation. The method involves using a compound that reduces the level of tyrosine phosphatase activity effected by the protein EYA1A in the parenchymal organ, a nucleic acid ligase IV inhibitor, or an antisense oligonucleotide against the p53-binding protein 1 (53BP1).
Type:
Application
Filed:
April 6, 2022
Publication date:
January 26, 2023
Applicants:
GEORG-AUGUST-UNIVERSITAET GOETTINGEN STIFTUNG OEFFENLICHEN RECHTS, UNIVERSITAETSMEDIZIN, BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM
Inventors:
Michael ZEISBERG, Elisabeth ZEISBERG, Bjoern TAMPE, Gerhard Anton MUELLER, Xingbo XU, Desiree TAMPE, Raghu KALLURI
Abstract: A vehicle composition in the form of a vesicular composition or a particular composition and, optionally, an active agent associated with the vesicle forming components or particles, and folate receptor alpha is used as a delivery system for the transport of components and/or active agents into the cerebrospinal fluid (CSF) and/or brain and/or central nervous system and/or spinal cord. The composition is used for treating of CSF or brain pertaining diseases, disorders or conditions, such as preventing or treating neurological or neurodegenerative diseases, disorders or conditions.
Type:
Grant
Filed:
October 12, 2012
Date of Patent:
April 24, 2018
Assignees:
Georg-August-Universität Göttingen Stiftung Öffenlichen Rechts, Universitätsmedizin, AllOrphan UG